ALL-1 |
Intermediate risk |
No |
No |
Chemotherapy |
6.2×10^-2 |
5.0×10^-4 |
In chemotherapy |
ALL-2 |
Low risk |
IKZF1, KMT2C, ASXL3, SMC1A |
No |
Chemotherapy |
- |
1.32×10-6 |
Drug withdrawal for one year |
ALL-3 |
Intermediate risk |
TP53, RB1, PIK3CD, USH2A |
No |
Chemotherapy |
1.0×10-3 |
Negative |
In chemotherapy |
ALL-4 |
High risk |
INRAS, KRAS, CSMD1, SOS1 |
No |
Chemotherapy |
3.0×10^e-3 |
2.1×10e-4 |
In chemotherapy |
ALL-5 |
Intermediate risk |
CREBBP, KRAS, IRF8, TBL1XR1 |
SPI1::ZNF384 |
Chemotherapy + blinatumomab |
2.0×10^e-2 |
8.0×10^e-5 |
In chemotherapy |
ALL-6 |
Intermediate risk |
NRAS, FLT3, IKZF3 |
DUX4::lgHJ6(582) |
Chemotherapy |
5.5×10^e-3 |
Negative |
In
chemotherapy |
ALL-7 |
Intermediate risk |
No |
No |
Chemotherapy |
1.0×10^e-4 |
Negative |
In chemotherapy |
ALL-8 |
Intermediate risk |
FLT3, PTPN11, KRAS, ETV6 |
EP300-ZNF384 |
Chemotherapy |
7.2×10e-3 |
4×10^e-5 |
In
chemotherapy |
ALL-9 |
Intermediate risk |
NRAS, KRAS |
No |
Chemotherapy |
2.2×10^e-3 |
Negative |
In chemotherapy |
ALL-10 |
High risk |
NRAS, KRAS, CREBBP |
No |
Chemotherapy +
blinatumomab |
1.3×10^e-2 |
Negative |
In chemotherapy |
ALL-11 |
Intermediate risk |
No |
TEL-AML1 |
Chemotherapy |
5.8×10^e-3 |
4×10^e-5 |
In chemotherapy |
ALL-12 |
Intermediate risk |
ASXL1, ATRX, CHD2 |
EP300-ZNF384 |
Chemotherapy |
2.0×10^e-4 |
Negative |
In
chemotherapy |